文献速递分子诊断临床微生物

三种SARS-CoV-2分子检测方法的临床评估与应用

Clinical Evaluation and Utilization of Multiple Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2.
PubMed 文献 · Am J Clin Pathol · 2020-01-01

该研究用184份鼻咽拭子比较Abbott ID NOW、DiaSorin Simplexa和Roche cobas三种SARS-CoV-2分子检测,并分析182例患者三种拭子类型及相对检出限。Abbott ID NOW阳性符合率91%,另两种为100%;三种方法阴性符合率均100%;PCR方法检出限比Abbott ID NOW低约10至100倍。

要点

  • Abbott ID NOW阳性符合率91%,DiaSorin Simplexa和Roche cobas均为100%。
  • 三种方法阴性符合率均100%,Abbott ID NOW对不同拭子类型结果一致。
  • PCR方法检出限比Abbott ID NOW低约10至100倍。

核心结论

  • 基于评估结果,建议根据患者人群和检测灵敏度采用多平台检测策略,以应对公共卫生紧急状态下的检测需求。

研究设计与样本

  • 使用184份鼻咽拭子标本比较Abbott ID NOW、DiaSorin Simplexa和Roche cobas三种SARS-CoV-2分子检测。
  • 另从182例急诊疑似COVID-19患者采集鼻咽、口咽和鼻腔三种拭子,用Abbott ID NOW检测。
  • 利用阳性鼻咽患者样本评估各方法的相对检出限。

主要发现

  • Abbott ID NOW阳性符合率为91%(95%CI 0.76-0.97)。
  • DiaSorin Simplexa和Roche cobas阳性符合率均为100%(95%CI 0.90-1.00)。
  • 三种方法阴性符合率均为100%(95%CI 0.98-1.00)。
  • Abbott检测的所有拭子类型结果一致。
  • PCR方法检出限比Abbott ID NOW低约10至100倍。

临床怎么用

  • 可根据患者人群和检测灵敏度需求选择不同分子检测平台。
  • 在公共卫生紧急状态下可采用多平台检测策略满足检测需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the clinical performance of 3 molecular assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS: We used 184 nasopharyngeal swab specimens to compare Abbott ID NOW COVID-19 (Abbott ID NOW), DiaSorin Molecular Simplexa COVID-19 Direct (DiaSorin Simplexa), and Roche cobas 6800 SARS-CoV-2 (Roche cobas) assays. In a separate analysis, 3 specimens (nasopharyngeal, oropharyngeal, and nasal) were collected from 182 unique patients presenting to the emergency department with suspicion of coronavirus disease 2019 and were tested utilizing Abbott ID NOW. To further characterize each assay, relative limits of detection were evaluated utilizing positive nasopharyngeal patient samples. RESULTS: The positive percent agreement was 91% (95% confidence interval [CI], 0.76-0.97) for Abbott ID NOW and 100% (95% CI, 0.90-1.00) for DiaSorin Simplexa and Roche cobas. The negative percent agreement was 100% (95% CI, 0.98-1.00) for all 3 assays. All swab types tested with the Abbott assay produced concordant results. Polymerase chain reaction assays had approximately 10 to 100 times lower limits of detection than Abbott ID NOW. CONCLUSIONS: Based on these evaluations, a multiplatform testing approach is proposed, depending on patient population and assay sensitivity, to address testing needs during a public health emergency.

来源:Am J Clin Pathol,查看原文。版权归原作者所有。

引用

  1. Cradic K, Lockhart M, Ozbolt P, et al. Clinical Evaluation and Utilization of Multiple Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2. Am J Clin Pathol. 2020. PMID: 32462195. doi:10.1093/ajcp/aqaa097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。